全文获取类型
收费全文 | 117篇 |
免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 11篇 |
妇产科学 | 8篇 |
基础医学 | 12篇 |
口腔科学 | 4篇 |
临床医学 | 16篇 |
内科学 | 16篇 |
皮肤病学 | 5篇 |
神经病学 | 7篇 |
外科学 | 21篇 |
综合类 | 1篇 |
预防医学 | 9篇 |
眼科学 | 1篇 |
药学 | 8篇 |
肿瘤学 | 5篇 |
出版年
2021年 | 3篇 |
2020年 | 1篇 |
2019年 | 6篇 |
2018年 | 6篇 |
2017年 | 7篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 7篇 |
2013年 | 7篇 |
2012年 | 10篇 |
2011年 | 5篇 |
2010年 | 8篇 |
2009年 | 5篇 |
2008年 | 4篇 |
2007年 | 11篇 |
2006年 | 9篇 |
2005年 | 8篇 |
2004年 | 6篇 |
2003年 | 2篇 |
2002年 | 3篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1995年 | 1篇 |
排序方式: 共有125条查询结果,搜索用时 24 毫秒
1.
George V Dedoussis Demosthenes B Panagiotakos Nikoleta V Vidra Eirini Louizou Christina Chrysohoou Athanasios Germanos Yannis Mantas Savas Tokmakidis Christos Pitsavos Christodoulos Stefanadis 《Genetics in medicine》2005,7(6):411-416
PURPOSE: We investigated the association of a polymorphism within the promoter of TauNuF-alpha locus at the position -308 on the likelihood of having acute coronary syndromes (ACS) in Greek adults. METHODS: We studied demographic, lifestyle, and clinical information in 237 hospitalized patients (185 males) with a first event of an ACS and 237 matched by age and sex (controls) without any clinical evidence of coronary heart disease. Genotyping was performed by PCR-RFLP analysis. RESULTS: The genotype frequencies were in patients, 87% (n = 206), 12% (n = 29), and 1% (n = 2) for G/G, G/A, and A/A, and in controls, 96% (n = 227), 4% (n = 10), and 0% (n = 0) for G/G, G/A, and A/A, respectively (P = 0.04). After adjusting for age and sex, as well as various potential confounders, we observed that G/A or A/A genotypes were associated with 1.94-fold higher odds (95% CI 1.06 to 3.68) of ACS compared to G/G homozygotes. No gene to-gender or to-clinical syndrome interactions were observed. Further subgroup analysis showed that the distribution of TNF-alpha -308G>A polymorphism was associated with the presence of family history of CHD in patients, but not in controls. In particular, in G/A and A/A patients 17.2% reported family history of CHD, whereas in G/G patients, 34.5% reported family history (P = 0.036). CONCLUSIONS: Our findings may state a hypothesis of an association between the -308G>A TNF-alpha polymorphism the development of ACS and the presence of family history of CHD, in Greece. 相似文献
2.
3.
4.
Trachana Maria Pratsidou-Gertsi Polyxeni Kanakoudi-Tsakalidou Florence Tzimouli Vasiliki Printza Nikoleta Papachristou Fotis 《Clinical rheumatology》2021,40(2):675-682
Clinical Rheumatology - This study on juvenile SLE patients aimed to evaluate retrospectively the impact of a tertiary center’s management policy of the disease severity on its long-term... 相似文献
5.
6.
Dagmara Borzych-Duzalka Yelda Bilginer Il Soo Ha Mustafa Bak Lesley Rees Francisco Cano Reyner Loza Munarriz Annabelle Chua Silvia Pesle Sevinc Emre Agnieszka Urzykowska Lily Quiroz Javier Darío Ruscasso Colin White Lars Pape Virginia Ramela Nikoleta Printza Andrea Vogel Dafina Kuzmanovska Eva Simkova Dirk E. Müller-Wiefel Anja Sander Bradley A. Warady Franz Schaefer for the International Pediatric Peritoneal Dialysis Network Registry 《Journal of the American Society of Nephrology : JASN》2013,24(4):665-676
Little information exists regarding the efficacy, modifiers, and outcomes of anemia management in children with CKD or ESRD. We assessed practices, effectors, and outcomes of anemia management in 1394 pediatric patients undergoing peritoneal dialysis (PD) who were prospectively followed in 30 countries. We noted that 25% of patients had hemoglobin levels below target (<10 g/dl or <9.5 g/dl in children older or younger than 2 years, respectively), with significant regional variation; levels were highest in North America and Europe and lowest in Asia and Turkey. Low hemoglobin levels were associated with low urine output, low serum albumin, high parathyroid hormone, high ferritin, and the use of bioincompatible PD fluid. Erythropoiesis-stimulating agents (ESAs) were prescribed to 92% of patients, and neither the type of ESA nor the dosing interval appeared to affect efficacy. The weekly ESA dose inversely correlated with age when scaled to weight but did not correlate with age when normalized to body surface area. ESA sensitivity was positively associated with residual diuresis and serum albumin and inversely associated with serum parathyroid hormone and ferritin. The prevalence of hypertension and left ventricular hypertrophy increased with the degree of anemia. Patient survival was positively associated with achieved hemoglobin and serum albumin and was inversely associated with ESA dose. In conclusion, control of anemia in children receiving long-term PD varies by region. ESA requirements are independent of age when dose is scaled to body surface area, and ESA resistance is associated with inflammation, fluid retention, and hyperparathyroidism. Anemia and high ESA dose requirements independently predict mortality.Almost three decades after the advent of recombinant erythropoietin, the management of renal anemia has become a recent focus of attention and changing paradigms. Whereas correction of hemoglobin (Hb) levels to near-normal has previously been recommended on the basis of association studies linking more severe anemia to morbidity and mortality with dialysis,1–3 interventional clinical trials consistently demonstrate that near-normalization of Hb increases the risk of vascular events and mortality in adults receiving maintenance hemodialysis and in those with CKD who are not undergoing dialysis.4–6 This has prompted ongoing reevaluation and revisions of treatment targets in patients exposed to erythropoiesis-stimulating agents (ESAs).7The appropriateness of applying treatment recommendations established in adult hemodialysis populations at high cardiovascular risk and adults with CKD to children undergoing dialysis is questionable because cardiovascular events are far less common in children with CKD. Furthermore, two thirds of children requiring dialysis initially opt for peritoneal dialysis (PD), and there are no systematic studies in the adult PD population to inform the optimal Hb target range in these patients. The risk profile of patients receiving PD may differ from that of the hemodialysis setting because of the absence of dialysis-induced intermittent hemoconcentration and lack of contact activation of the complement and coagulation systems.Further aspects to consider in pediatric anemia management are the greater physical activity of children and the need for optimal cognitive functioning at school.8,9 The significant physiologic variation of the normal Hb range with age10 and the relative ESA sensitivity that reportedly increases with age during early childhood are also noteworthy.11The registry of the International Pediatric Peritoneal Dialysis Network (IPPN) prospectively collects detailed clinical, biochemical, dialysis, and medication-related information (including ESA types and doses and modalities of iron supplementation) from a substantial number of children undergoing long-term PD around the world. In-depth analysis of this unique database has allowed us to (1) gain insight into the demographic characteristics of renal anemia and its treatment in the pediatric PD population worldwide, (2) explore the relationship between ESA dose requirements and body dimensions, (3) identify factors contributing to ESA resistance in children, and (4) associate anemia control with patient outcomes. 相似文献
7.
Anthi Hassani Mariana C. Kotzamanidou Eleni Fotiadou Dimitrios Patikas Christina Evagelinou Nikoleta Sakadami 《Research in developmental disabilities》2013,34(9):2856-2863
The purpose of this study was to identify the differences in vertical squat jump (SJ) between volunteers with and without intellectual disability (ID). Thirteen boys with ID (average intelligence quotient, estimated by Wisk III test: 55.6 ± 11.2) and 13 peers without disabilities performed maximal SJ on a force platform. Kinematic data were captured using a six-camera 3D motion analysis system and electromyographic (EMG) activity was recorded using surface electrodes. Unpaired T-test determined the statistical difference between the two groups. The obtained results indicated that the group with ID, jumped lower, developed lower vertical ground reaction forces, knee power output, knee angular velocity, and take-off velocity, and showed longer propulsion duration, decreased mean to maximum agonist EMG activity and higher antagonist/agonist activity ratio. The deficit in the SJ observed in individuals with ID was attributed to a deficit in the examined mechanical and neuromuscular parameters, and especially to the agonist and antagonist co-contraction. 相似文献
8.
Stella Stabouli Eleni Papadimitriou Nikoleta Printza John Dotis Fotios Papachristou 《Pediatric nephrology (Berlin, Germany)》2016,31(8):1221-1229
The prevalence of sleep disorders during childhood has been estimated to range from 25 to 43 %. The aim of this review is to determine the prevalence of sleep disorders and possible associations with chronic kidney disease (CKD)-related factors and health-related quality of life (HRQOL) in children with CKD. An electronic systematic literature search for sleep disorders in children with CKD in Pubmed, Embase and the Cochrane Library Databases identified seven relevant articles for review, all of which reported an increased prevalence of sleep disorders in children with CKD. Five studies included children with CKD undergoing dialysis, and two studies included only non-dialysis patients. In all studies the presence of sleep disturbances was assessed by questionnaires; only one study compared the results of a validated questionnaire with laboratory-based polysomnography. The prevalence of any sleep disorder ranged from 77 to 85 % in dialysis patients, to 32–50 % in transplanted patients and 40–50 % in non-dialysis patients. The most commonly studied disorder was restless legs syndrome, which presented at a prevalence of 10–35 %. Three studies showed significant associations between presence of sleep disorders and HRQOL. We found consistent evidence of an increased prevalence of sleep disturbances in children with CKD, and these seemed to play a critical role in HRQOL. 相似文献
9.
John Dotis Pavlos Myserlis Nikoleta Printza Stella Stabouli Chrysa Gkogka Antigoni Pavlaki 《Renal failure》2016,38(7):1031-1035
Peritoneal dialysis (PD) constitutes the preferred dialysis modality for children requiring renal replacement therapy with peritonitis being one of the most common complications of PD. This study was performed to evaluate the epidemiology, microbiology, and outcomes of PD-associated peritonitis in Greek children for a 10-year period. A total of 27 patients (16 males) with a mean age 121.8?±?57.2 months were retrospective analyzed. Patients were on PD therapy for a mean duration of 45.2?±?26.1 months. We found 23 episodes of PD-associated peritonitis occurred in 9 out of 27 patients (0.23 episodes/patient-year), with four patients experienced two or more peritonitis episodes. Gram-positive bacteria were responsible for 15 (65.2%) peritonitis episodes, with Staphylococcus aureus being the predominant specie isolated in 30.4% of cases. A total of seven episodes of exit-site infections (ESIs) were identified in five patients (0.069 episodes/patient-year) with the most common bacteria isolated being S. aureus (57.4%). Initial antibiotic treatment included intraperitoneal vancomycin plus ceftazidime in the majority of cases (82.6%). At the end of study, 12 (44.4%) patients remained on PD, 11 (41.8%) underwent renal transplantation, 2 (7.4%) shifted to hemodialysis and unfortunately, two patients (7.4%) died. Conclusively, our study revealed a noticeable low peritonitis and ESIs rate as compared to international data and represents the first evaluation of the characteristics and outcomes of peritonitis in the Greek pediatric PD population. 相似文献
10.